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TNF has remarkable antitumor activities; however, therapeutic applications have not been possible because 
of the systemic and lethal proinflammatory effects induced by TNF. Both the antitumor and inflammatory 
effects of TNF are mediated by the TNF receptor p55 (p55TNFR) (encoded by the Tnfrsf1a gene). The anti-
tumor effect stems from an induction of cell death in tumor endothelium, but the cell type that initiates the 
lethal inflammatory cascade has been unclear. Using conditional Tnfrsf1a knockout or reactivation mice, we 
found that the expression level of p55TNFR in intestinal epithelial cells (IECs) is a crucial determinant in TNF-
induced lethal inflammation. Remarkably, tumor endothelium and IECs exhibited differential sensitivities 
to TNF when p55TNFR levels were reduced. Tumor-bearing Tnfrsf1a+/– or IEC-specific p55TNFR-deficient 
mice showed resistance to TNF-induced lethality, while the tumor endothelium remained fully responsive to 
TNF-induced apoptosis and tumors regressed. We demonstrate proof of principle for clinical application of 
this approach using neutralizing anti-human p55TNFR antibodies in human TNFRSF1A knockin mice. Our 
results uncover an important cellular basis of TNF toxicity and reveal that IEC-specific or systemic reduction 
of p55TNFR mitigates TNF toxicity without loss of antitumor efficacy.
Introduction
In high doses, TNF has remarkable antitumor effects, especially 
when it is combined with IFN-γ and/or chemotherapeutics (1). 
Unfortunately, TNF also possesses strong proinflammatory prop-
erties, and its use is often accompanied by unacceptable shock 
symptoms, such as hypotension and organ failure (2–4). Initial 
studies in patients showed that the maximum tolerated dose 
(MTD) that can be applied systemically in humans is too low for 
effective tumor therapy (5). Therefore, therapeutic anticancer 
application of TNF is limited to local settings, such as isolated 
limb perfusion, which does not cause systemic toxicity but leads to 
a very high rate of complete regression of melanomas and soft tis-
sue sarcomas, avoiding amputation of the extremities (6–8). Such 
successes illustrate that TNF has great potential as an anticancer 
drug, providing that its toxicity can be reduced (9).
TNF acts by binding to two different receptors, TNF recep-
tor p55 (p55TNFR) (Tnfrsf1a) and p75TNFR (Tnfrsf1b) (10). The 
p55TNFR was identified as the receptor responsible for both the 
antitumor effects (11–14) and the shock-inducing proinflam-
matory signals induced by TNF (12, 15), whereas p75TNFR has 
been implicated mainly in immune modulation (16) and plays 
no significant role in TNF’s toxicity (15). The default pathway of 
p55TNFR signaling, activated in most cell types, leads to cell sur-
vival and induction of inflammation, but when cells fail to suffi-
ciently induce these survival signals, an alternate pathway leading 
to cell death is activated (17, 18). In contrast to initial beliefs, the 
antitumor effects of TNF are not due to direct induction of cell 
death of tumor cells. Evidence suggests that TNF directly affects 
the tumor neovasculature, causing endothelial cell death and vas-
cular dysfunction, leading to tumor necrosis (11, 19, 20).
While the cellular target of the TNF-induced antitumor effects 
has been elucidated, the mechanisms and the tissues involved 
in TNF-induced toxicity have only been partially characterized. 
Recently, a role for necroptosis in TNF-induced toxicity was 
uncovered (21), but earlier work stresses the importance of TNF-
mediated induction of inflammation (e.g., classical antiinflam-
matory drugs such as steroids and indomethacin protect against 
TNF toxicity; refs. 22, 23) and of inflammatory mediators, such 
as IL-17, IL-1, IFN-β, ROS, and iNOS (24–28). Multiple organs, 
such as intestine, liver, and kidney, suffer from the TNF-induced 
effects, but it is still unclear which cell type is essential in medi-
ating/initiating the TNF-induced toxicity (2, 29, 30). Of interest, 
several acute inflammatory conditions in which TNF plays a role 
have been attributed to effects on the intestinal epithelial cells 
(IECs) (31, 32).
In this study, we addressed the question of whether TNF’s 
anticancer and proinflammatory effects can be uncoupled, 
leading to safer anticancer effects. We report that reducing the 
expression or availability of p55TNFR strongly dampens the 
proinflammatory signal without affecting the induction of 
apoptosis and antitumor effects. Moreover, using conditional 
Tnfrsf1a reactivation mice, we demonstrate that p55TNFR 
expression in IECs is sufficient to induce lethal toxicity, while 
conditional Tnfrsf1a-deficient mice prove that a reduction in 
p55TNFR expression in IECs significantly protects against 
lethal TNF-induced toxicity. Our findings uncover an important 
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cellular basis of systemic TNF toxicity, reveal an IEC-specific 
haploinsufficiency of p55TNFR, and lay the ground for safe and 
effective TNF-based antitumor treatment strategies.
Results
A 50% reduction of p55TNFR completely protects mice against acute TNF. 
Three different Tnfrsf1a–/– mouse lines have been generated using 
different targeting strategies (12–14). All of them were extreme-
ly resistant to the lethal inflammatory effect of TNF (Table 1). 
Hemizygous Tnfrsf1a mice were equally resistant to a single TNF 
injection and easily tolerated 1,000 μg per mouse (Table 1), i.e., 
40-fold more than Tnfrsf1a+/+ mice, whose LD100 was 25–30 μg. 
Upon injection of murine TNF at 100 μg per mouse, Tnfrsf1a+/+ 
mice died from inflammation within 24 hours, but no effects were 
observed in Tnfrsf1a+/– mice (data not shown). In addition, TNF-
induced IL-6 was absent in the sera of all Tnfrsf1a–/– lines and was 
significantly lower (on average 32.5 fold) in Tnfrsf1a+/– mice than 
in Tnfrsf1a+/+ mice after TNF injection (Figure 1A). The results were 
independently confirmed in the 3 different types of Tnfrsf1a–/– and 
Tnfrsf1a+/– mouse lines. Subsequent experiments were performed 
on one type of Tnfrsf1a–/– line, namely the one generated by Rothe 
et al. (12). In contrast to Tnfrsf1a+/– and Tnfrsf1a–/– mice, Tnfrsf1a+/+ 
mice challenged with TNF displayed hypothermia (Figure 1B), 
sickness symptoms (ruffled fur, diarrhea, and physical inactiv-
ity) (Figure 1C), and liver and kidney damage (Figure 1D and 
Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI65624DS1) as well as increases 
in plasma hexosaminidase and LDH, general markers of cellular 
damage (Supplemental Figure 1, B and C). The intestinal barrier 
function, measured by leakage of orally gavaged FITC-dextran into 
the blood, was significantly affected in Tnfrsf1a+/+ mice, but not in 
Tnfrsf1a+/– mice, 8 hours after TNF challenge (Figure 1E).
The amount of cell-associated p55TNFR protein in livers, lungs, 
and other organs of hemizygous mice was about half of that in 
Tnfrsf1a+/+ mice (Figure 1F and Supplemental Figure 1, D–F). These 
results were confirmed by qPCR, which showed that livers of Tnfr­
sf1a+/– mice had about half of the p55TNFR mRNA of Tnfrsf1a+/+ 
mice (Supplemental Figure 1G). Binding studies using I125-labeled 
human TNF (125I-hTNF), which binds mouse p55TNFR (mp55-
TNFR) but not mouse p75TNFR (33), showed that binding is 
reduced by about half in Tnfrsf1a+/– bone marrow–derived macro-
phages (BMDMs) compared with Tnfrsf1a+/+ BMDMs (Figure 1G). 
Finally, p55TNFR expression was measured on Tnfrsf1a+/– cells 
by FACS and was intermediate between Tnfrsf1a+/+ and Tnfrsf1a–/– 
BMDMs (Supplemental Figure 1H).
TNF­induced inflammation is strongly reduced in Tnfrsf1a+/– mice. To 
explain the reduced induction of inflammation in Tnfrsf1a+/– cells, 
we isolated BMDMs and thioglycolate-elicited peritoneal macro-
phages from the 3 different genotypes, Tnfrsf1a+/+, Tnfrsf1a+/–, and 
Tnfrsf1a–/–, and stimulated them in vitro with TNF. In this setup, 
we looked at different steps of p55TNFR-mediated inflamma-
tion, such as NF-κB and MAPK activation and production of IL-6. 
NF-κB activation was studied by IκB degradation (Supplemental 
Figure 2A) and EMSA (Figure 2A and Supplemental Figure 2B). 
The incomplete degradation of IκB in Tnfrsf1a+/– cells was con-
firmed by the reduced activation and nuclear translocation of 
NF-κB compared with that in Tnfrsf1a+/+ cells. Similarly, phosphor-
ylation of the MAPKs JNK2 and ERK was reduced in Tnfrsf1a+/– cells 
compared with that in Tnfrsf1a+/+ cells (Figure 2, B and C, and Sup-
plemental Figure 2, C and D). Accordingly, the induction of IL-6 
after TNF stimulation in Tnfrsf1a+/– mice was significantly lower 
than that in Tnfrsf1a+/+ mice at 24 hours (Supplemental Figure 2E).
Similar experiments performed in vivo showed that degradation 
of IκB in the liver was undetectable in TNF-injected Tnfrsf1a–/– 
mice and was reduced significantly in Tnfrsf1a+/– mice compared 
with that in Tnfrsf1a+/+ mice (Supplemental Figure 2F). Similar 
data were obtained in lungs (data not shown). To know whether 
this leads to reduced TNF-induced toxicity, we injected mice with a 
single dose of 30 μg TNF and measured the expression of NF-κB–
dependent genes in the liver by qPCR 0, 1, and 6 hours after chal-
lenge. The expression of IKBA, Il1b, IFN­β, Cxcl9, c­FLIP, and Nox2 
was significantly lower (~50%) in Tnfrsf1a+/– mice than that in Tnfr­
sf1a+/+ mice (Figure 2, D–F, and Supplemental Figure 2, G–I). The 
same pattern was found for a whole set of other NF-κB–inducible 
genes, including A20, Icam1, and Vcam1 (data not shown). We also 
measured serum cytokine levels after TNF stimulus and found 
that, while no induction was observed in Tnfrsf1a–/– mice, most of 
them were half-maximally induced in Tnfrsf1a+/– mice: IL-1β and 
IL-12p40 (Figure 2, G and H) as well as IL-1α, MIP1β, MCP-1, and 
CCL5/Rantes (Supplemental Figure 2, J–M). In addition, we found 
half the amount of NO metabolites in Tnfrsf1a+/– mice compared 
with that in Tnfrsf1a+/+ mice (Figure 2I).
The strong protection of Tnfrsf1a+/– mice from TNF and the gen-
eral reduction of expression of genes that have previously been 
shown to mediate TNF toxicity is consistent with a model in which 
TNF toxicity is indirect and mediated by several molecules, a com-
bined reduction of which leads to accumulating protection. To 
verify this hypothesis, we studied the effect of inhibition of mul-
tiple proven toxic mediators on injection of 37.5 μg TNF, a 1.5-
times LD100 dose. Type I IFNs were inhibited genetically by using 
Ifnar1–/– animals (27), ROS were inhibited using tempol (28), and 
IL-1 was inhibited using IL-1RA (25). The inhibition of all 3 toxic 
mediators indeed resulted in a cumulative protection against TNF 
(Figure 2, J and K).
Beneficial functions of TNF are preserved in Tnfrsf1a+/– mice. We inves-
tigated whether genetic reduction of p55TNFR expression com-
promises the beneficial physiological functions of TNF, such as 
resistance to infection and immune function. First, the Tnfrsf1a+/+, 
Tnfrsf1a+/–, and Tnfrsf1a–/– mice were infected with Listeria monocy­
togenes. The Tnfrsf1a–/– mice succumbed to the infection, but all 
Table 1
Lethal effect of 3 different doses of i.p. TNF in 3 types  
of Tnfrsf1a–/– mice
   TNF doses
  100 μg 250 μg 1,000 μg
Tnfrsf1a+/+  36/36 6/6 ND
Tnfrsf1a–/– Rothe 0/6 0/6 0/6
 Peschon 0/4 0/2 0/2
 Pfeffer 0/4 0/2 ND
Tnfrsf1a+/– Rothe 0/8 0/6 0/6
 Peschon 0/8 0/2 0/2
 Pfeffer 0/8 0/2 0/2
The ratio of dead mice to the total number of experimental mice 3 days 
after injection of the indicated doses of mouse TNF is shown for the 
Rothe (12), Peschon (13), and Pfeffer (14) homozygous or heterozygous 
Tnfrsf1a-deficient mouse lines. ND, not done.
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Tnfrsf1a+/+ and Tnfrsf1a+/– mice survived (Figure 3A). We then exam-
ined the structure of lymphoid organs and humoral immune 
responses, both dependent on Tnfrsf1a (34), in Tnfrsf1a+/– mice. 
Spleen sections were made from mice 15 days after immuniza-
tion with sheep red blood cells (SRBCs). These sections showed 
that germinal centers and follicular dendritic cell networks were 
present in Tnfrsf1a+/+ and Tnfrsf1a+/– mice but missing in Tnfrsf1a–/– 
mice (Figure 3B). In addition, a significant antibody response 
against SRBCs was detected in Tnfrsf1a+/– mice, while no antibody 
response was observed in Tnfrsf1a–/– mice (Figure 3C).
p55TNFR expression in the IECs is essential to induce TNF toxicity. To 
identify which cell type crucially regulates TNF-induced toxicity, 
we used two complementary approaches. In a first approach, we 
made use of mice expressing a Tnfrsf1a conditional reactivation 
mutant allele, Tnfrsf1aflNeo mice (35, 36). Crossing these mice with 
tissue-specific Cre-lines yielded Tnfrsf1a+/flNeo mice expressing Tnfr­
sf1a+/– levels in all cell types, except in those cells expressing Cre, in 
which Tnfrsf1a+/+ levels are obtained. Crosses with Tie2­ and Flk1­
Cre mice (endothelial cell reactivation), Albumin­ and Alfp­Cre mice 
(hepatocyte reactivation), LysM­Cre mice (myeloid cell reactivation), 
Figure 1
Resistance of Tnfrsf1a+/– mice to TNF-induced lethal inflammation. (A) Serum IL-6 6 hours after a single i.p. injection of 100 μg TNF in the 
Rothe (12), Pfeffer (14), and Peschon (13) Tnfrsf1a-deficient mouse lines. ***P < 0.001, compared with Tnfrsf1a+/+. (B) Body temperature 
(***P < 0.001, compared with Tnfrsf1a+/– and Tnfrsf1a–/–), (C) sickness score, (D) serum AST and ALT levels, and (E) intestinal permeabil-
ity of Tnfrsf1a+/+, Tnfrsf1a+/–, and Tnfrsf1a–/– mice after i.p injection with 50 μg TNF i.p. (or 25 μg i.p. for permeability assay) (n = 8 for all 
groups). (F) p55TNFR expression, measured by ELISA, in liver samples. (G) Specific binding of 125I-hTNF to BMDMs. In D and F, levels in 
Tnfrsf1a–/– and Tnfrsf1a+/– were 0, so no statistical significance could be calculated toward Tnfrsf1a+/+ data. Data represent mean ± SEM. 
*P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test).
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Figure 2
Signal transduction, gene expression, and cytokine release induced by TNF in Tnfrsf1a+/– mice. (A) Quantification of NF-κB EMSA results in 
nuclear extracts of BMDMs after stimulation with 10 ng/ml TNF. The graph shows intermediate activation of NF-κB in the Tnfrsf1a+/– samples 
compared with the Tnfrsf1a+/+ and Tnfrsf1a–/– samples. (B and C) Quantification of Western blot results showing JNK and ERK phosphory-
lation in BMDMs at several time points after stimulation with 10 ng/ml TNF. See also Supplemental Figure 2, B–D, for original blots. (D–F) 
Intermediate induction of genes coding for IKBA, IL-1β, and IFN-β in livers of mice injected i.p. with 30 μg TNF. Data for Tnfrsf1a–/– mice are 
not shown, because these mice are not responsive to TNF. (G–I) Intermediate IL-1β, IL-12p40, and NOx release in sera of Tnfrsf1a+/– mice 
injected with 30 μg TNF. (J and K) Cumulative protection against hypothermia and lethality induced by injection of 37.5 μg TNF (1.5-times 
LD100 in Tnfrsf1a+/+ mice). Ifnar1+/+ mice (n = 7) were compared with Ifnar1–/– mice (n = 10), which were protected by the ROS inhibitor Tempol 
(n = 9) or by Tempol and IL-1RA (Anakinra) (n = 10). Numbers in parentheses indicate the number of mice in each group that did not survive. 
Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test in D–I and log-rank test in K).
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and Villin­Cre mice (IEC reactivation) were performed (Supple-
mental Figure 5A), and the resulting mice were injected with TNF. 
Only the mice with Villin­Cre–induced reactivation displayed sen-
sitivity for TNF-induced toxicity and lethality, suggesting a crucial 
role for gut epithelium (Figure 4A). Villin­Cre–reactivated mice, in 
contrast to nonreactivated Tnfrsf1a+/flNeo mice, showed loss of intes-
tinal permeability upon TNF challenge (ref. 37 and Figure 4B) and 
increased intestinal Il6 and Il17a mRNA expression (Supplemental 
Figure 5B). Intestine-derived IL-17 has previously been linked to 
TNF toxicity (24). Induction of NF-κB–mediated genes by TNF, 
as shown before in liver (Figure 2), was strongly reduced in intes-
tinal tissues derived from Tnfrsf1a+/– mice compared with that in 
Tnfrsf1a+/+ mice (Supplemental Figure 3, A–D), whereas TNF-medi-
ated IEC death sensitivity remained unaffected (Figure 4C).
To further investigate the cell-specific requirement of p55TNFR 
in TNF-induced toxicity, we generated Tnfrsf1a conditional knock-
out mice (Tnfrsf1afl/fl mice) (the generation and initial characteriza-
tion of these mice are described in the Methods and in Supplemen-
tal Figure 4). Crossing the LysM­Cre, Villin­Cre, or Alfp­Cre strains 
into the Tnfrsf1afl/fl background resulted in p55TNFR inactivation 
in myeloid cells, IECs, or hepatocytes, respectively (Supplemental 
Figure 4, D–F). Only the Villin­Cre Tnfrsf1afl/fl mice significantly 
resisted TNF-induced toxicity, in contrast to the mice with hepa-
tocyte or myeloid cell Tnfrsf1a deficiency, which remained as sensi-
tive as the controls (Supplemental Figure 5C). Villin­Cre Tnfrsf1afl/fl 
mice showed reduced intestinal permeability (Supplemental Fig-
ure 5D) as well as decreased levels of Il6, Il1b, and Il17a mRNA in 
intestinal tissue in comparison with that in controls (Supplemen-
tal Figure 5E). Interestingly, when TNF was injected in the Villin­
Cre Tnfrsf1afl/+ mice, the mice were as resistant to TNF toxicity as 
the Villin­Cre Tnfrsf1afl/fl mice (Figure 4, D and E). The Villin­Cre 
Tnfrsf1afl/+ mice exhibited a minimal barrier loss compared with 
non-TNF-challenged Villin­Cre Tnfrsf1afl/+ control mice, but the 
barrier was significantly less affected than in TNF-challenged 
Tnfrsf1afl/+ mice (Figure 4E). We also noticed that IEC death was 
not defective in Villin­Cre Tnfrsf1afl/+ mice compared with that in 
p55TNFR-sufficient control mice (Figure 4, C and F), suggesting 
that TNF-induced systemic death is related to TNF-induced loss 
of IEC barrier rather than to TNF-induced IEC cell death. In con-
clusion, these results show that p55TNFR expression levels in the 
IECs are crucially linked with the induction of intestinal perme-
ability and consequent systemic lethal inflammation.
p55TNFR­dependent apoptosis induction remains functional in Tnfr­
sf1a+/– mice. To characterize TNF-induced apoptosis in Tnfrsf1a+/– 
cells, we studied the TNF response of primary fibroblasts derived 
from Tnfrsf1a+/+, Tnfrsf1a+/–, and Tnfrsf1a–/– mice. When cells were 
treated with TNF for 24 hours, intermediate production of IL-6 
in supernatant of Tnfrsf1a+/– cells was found (Figure 5A). However, 
when apoptosis was induced by incubation of cells with TNF and 
cycloheximide (CHX) for 24 hours, an equal amount of cell death 
Figure 3
Antimicrobial effects, immune response, and spleen germinal centers in Tnfrsf1a+/– mice. (A) Survival of mice following i.p. challenge with 105 Lis-
teria monocytogenes per mouse. (B) Germinal center formation and follicular dendritic cell networks in spleens of mice immunized with SRBCs 
are evident after staining with either PNA (blue) or CR-1 (brown). In Tnfrsf1a+/+ and Tnfrsf1a+/– mice, germinal centers and follicular dendritic 
cell networks are both detected, but they are absent in Tnfrsf1a–/– mice. Original magnification, ×40. (C) Serum antibody responses to SRBC 
immunization. Data are expressed in arbitrary units as the mean ± SEM of at least 10 mice per group and are representative of 3 independent 
experiments. **P < 0.01, ***P < 0.001.
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Figure 4
p55TNFR expression in the intestinal epithelium is a critical determinant for TNF-induced toxicity. (A) Tnfrsf1a+/–, Tnfrsf1a+/flNeo, and Tnfrsf1a+/flNeo mice 
with tissue-specific Cre expression were injected i.p. with 150 μg TNF, and lethality was monitored. (B) Relative intestinal permeability measured by 
increase in FITC signal in plasma of Tnfrsf1a+/flNeo (gray) and Tnfrsf1a+/flNeo IEC reactivation mice (black) orally gavaged with 4-kDa FITC-dextran and 
injected with TNF (0 hour, n = 3; 8 hours, n = 8). (C) IEC death in Tnfrsf1a+/+, Tnfrsf1a+/–, Tnfrsf1a+/flNeo, and Villin-Cre+ Tnfrsf1a+/flNeo mice 2 hours after 
TNF challenge (30 μg, i.p.). Similar amounts of TUNEL-positive cells on ileal sections were detected in all samples (n = 4–5; scale bar: 38 μm). Multiple 
time points (1, 4, and 8 hours after TNF) were tested, and all showed a similar amount of TUNEL-positive cells in Tnfrsf1a+/+ and Tnfrsf1a+/– IECs. (D) 
Tnfrsf1afl/fl (black line), Villin-Cre Tnfrsf1afl/+ (light gray line), and Villin-Cre Tnfrsf1afl/fl (dark gray line) mice were injected i.v. with 6 μg TNF, and lethality 
was monitored. (E) Relative intestinal permeability of Villin-Cre Tnfrsf1afl/+ mice compared with Tnfrsf1afl/+ mice when mice were injected with 7 μg TNF 
and orally gavaged with 4-kDa FITC-dextran (0 hours, n = 5; 8 hours, n = 11). (F) IEC death in Tnfrsf1a–/–, Tnfrsf1a+/fl, and Villin-Cre Tnfrsf1a+/fl mice 2 
hours after TNF challenge (6 μg, i.v.). Similar amounts of TUNEL-positive cells on ileal sections were detected in all samples (n = 6; scale bar: 38 μm). 
Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test in B and E, and log-rank test in A and D).
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induction was observed in Tnfrsf1a+/+ and Tnfrsf1a+/– cells (Figure 
5B). Western blot analysis of caspase-8 activation at different time 
points after TNF/CHX stimulation showed that both Tnfrsf1a+/+ 
and Tnfrsf1a+/– fibroblasts activate similar levels of caspase-8 (Fig-
ure 5C). We then induced apoptosis in vivo by injecting TNF plus 
d-galactosamine (GalN). This combination leads to lethal apopto-
sis in hepatocytes (38). First, we tested the lethality of two different 
doses of TNF (0.3 and 0.5 μg) combined with 20 mg GalN. While 
none of the Tnfrsf1a–/– mice died from the higher dose, all of the 
Tnfrsf1a+/– mice and 24 out of the 26 Tnfrsf1a+/+ mice died within 
72 hours (Supplemental Figure 6A). Next, mice were injected with 
1 μg TNF and 20 mg GalN and sacrificed when their body tempera-
ture dropped to 30°C, and blood and liver samples were obtained. 
This occurred at 7 and 7.5 hours in Tnfrsf1a+/+ and Tnfrsf1a+/– mice, 
respectively (Figure 5D). Tnfrsf1a–/– mice were unresponsive to the 
treatment, and their samples were taken 8 hours after challenge. 
Liver damage was assessed by measurement of alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) in serum (Figure 
5E), and apoptosis was measured by DEVDase assay in liver lysates 
(Figure 5F). AST and ALT levels in Tnfrsf1a+/+ and Tnfrsf1a+/– mice 
were not significantly different, indicating comparable amounts of 
liver damage. No significant differences were observed in the cleav-
age of the caspase-3/7 substrate DEVD, indicating comparable 
induction of apoptosis in Tnfrsf1a+/+ and Tnfrsf1a+/– mice. We also 
studied apoptosis by using the TNF/actinomycin D (TNF/ActD) 
model and obtained similar results (Supplemental Figure 6, B and 
C). These results, along with the in vivo results of p55TNFR-medi-
ated death in the intestine (Figure 4, C and F), show that induction 
of apoptosis by TNF is intact in Tnfrsf1a+/– genotypes.
TNF/IFN­γ–induced apoptosis in tumor endothelium. Effective TNF/
IFN-γ–based antitumor therapy induces apoptosis in the neovas-
culature of tumors, and this is considered key to tumor destruc-
tion (7, 20). To study the induction of apoptosis in the tumor 
endothelium, B16BL6 tumor-bearing Tnfrsf1a+/+, Tnfrsf1a+/–, and 
Tnfrsf1a–/– mice were injected s.c. paralesionally with 15 μg TNF 
and 5,000 IU IFN-γ or with PBS, and 24 hours later tumors were 
excised and apoptosis and caspase-3/7 activation were measured 
by FACS. The percentage of apoptotic tumor endothelial cells, 
identified as CD31+CD45–PI– cells, was measured using annexin 
V and Flica staining, respectively. Figure 5, G and H shows the 
increase of annexin V–stained cells and Flica-stained cells in TNF/
IFN-γ–injected mice compared with that in PBS-treated mice. 
Tnfrsf1a+/+ and Tnfrsf1a+/– mice showed comparable degrees of 
apoptotic annexin V–positive cells (Figure 5G) and Flica-positive 
cells containing active caspases (Figure 5H). No increase in annex-
in V– and Flica-positive cells was observed in Tnfrsf1a–/– mice.
TNF/IFN­γ therapy in Tnfrsf1a+/– mice induces tumor regression in the 
absence of systemic toxicity. We first studied the toxicity profile of 
standard TNF/IFN-γ therapy, i.e., daily paralesional injection dur-
ing 10 days, in Tnfrsf1a+/+ and Tnfrsf1a+/– tumor-free mice as well 
as in mice bearing a s.c. B16BL6 melanoma. The tumor regresses 
well in response to TNF, but it also sensitizes mice to TNF toxic-
ity (39). The LD50 dramatically increased 12.1 fold in tumor-free 
mice and 8.2 fold in tumor-bearing Tnfrsf1a+/– mice relative to that 
in Tnfrsf1a+/+ mice (Figure 6A and Supplemental Figure 7A). This 
therapeutic window in Tnfrsf1a+/– mice is close to the required 
10-fold factor increase in MTD that was proposed to be essential 
to increase the safety of TNF to an acceptable level (5). These data 
suggest that a full and safe antitumor effect may be expected in 
Tnfrsf1a+/– mice, so we performed antitumor experiments in 2 dif-
ferent models using high doses of TNF/IFN-γ. As shown in Figure 
6, B and C, established B16BL6 and Lewis lung carcinoma (LLC) 
tumors did not regress in Tnfrsf1a–/– mice, and all Tnfrsf1a+/+ mice 
died on the second day of TNF/IFN-γ treatment due to inflam-
matory shock. In contrast, Tnfrsf1a+/– mice remained healthy, and 
tumors regressed either completely or to a very large extent after 
10 days of treatment. Further proof that p55TNFR expression on 
host-derived cells but not on tumor cells sensu stricto is linked 
to the response to TNF/IFN-γ is discussed in Supplemental Fig-
ure 7B, where we show that TNF-mediated tumor regression is 
dependent on p55TNFR expression of the host tissue but not on 
the tumor cells themselves. To further explore the role of TNF-
p55TNFR-mediated toxic signaling through IECs, we performed 
the antitumor experiment using high doses of TNF/IFN-γ in Vil­
lin­Cre Tnfrsf1afl/fl mice. Tumor regression occurred equally well in 
both groups of mice, but survival was significantly better in Villin­
Cre Tnfrsf1afl/fl mice (Figure 6D). We conclude that a general reduc-
tion of p55TNFR levels by 50% or in a IEC-specific manner greatly 
reduces TNF-induced toxicity without diminishing the antitumor 
effects. This can make TNF therapy both safe and effective.
Systemic administration of anti­p55TNFR antibody strongly protects 
against TNF­induced toxicity and leads to safe antitumor therapy. To 
assess clinical applicability, we used two approaches based on 
using antibodies to neutralize p55TNFR. First, an anti-mp55TN-
FR monoclonal antibody protected mice against acute TNF lethal-
ity in a dose-responsive way (Figure 7A) and protected B16BL6 
tumor-bearing mice against toxicity of TNF/IFN-γ therapy with-
out loss of the anticancer effect, while mice treated with a con-
trol antibody showed no significant difference compared with 
PBS-treated animals. (Figure 7, B and C). Elaborate dose-response 
studies (see Methods) showed an increase of LD50 of 4 times using 
cotreatment with the antibody compared with the control anti-
body (Figure 7D and Supplemental Figure 7A). Second, we used 
a newly developed human TNFRSF1A knockin humanized mouse 
model (Supplemental Figure 8) and examined the therapeutic 
efficacy of an anti-human p55TNFR (anti-hp55TNFR) PEGylat-
ed Fab’ fragment that neutralizes human but not mp55TNFR. 
Administration of this antibody (10 mg/kg) prevented acute TNF 
lethality in human TNFRSF1A knockin mice (Figure 7E) but not in 
wild-type mice (data not shown). The specific protective effect of 
coadministration of the antibody in tumor treatment settings was 
evaluated using the B16BL6 tumor model. Notably, the antibody 
conferred complete protection against lethality, while the antitu-
mor effect was fully preserved (Figure 7, F and G). The magnitude 
of the protection studied in an elaborate and standard LD50 experi-
ment was 5 times (Figure 7H). This was a slight improvement over 
the anti-mp55TNFR antibody, possibly because of better pharma-
cokinetics of the PEGylated Fab′ fragment compared with the clas-
sical anti-mp55TNFR antibody (Supplemental Figure 7A).
Discussion
TNF was first discovered as a cytokine that can cause death of 
tumor cells and regression of established, solid tumors (4, 40). 
Shortly afterward, TNF was rediscovered as cachectin, a cytokine 
responsible for cachexia during chronic infection (41). The dilem-
ma that TNF has strong anticancer effects but is toxic was con-
firmed in the first clinical trials (42). The effective anticancer dose 
of TNF was found to be high, close to the MTD, and to be associ-
ated with liver toxicity, shock, and bowel necrosis. Lowering the 
dose of TNF reduced side effects but also the anticancer effect (1). 
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Figure 5
Induction of apoptosis in Tnfrsf1a+/– mice. (A) IL-6 production in supernatant of Tnfrsf1a+/+, Tnfrsf1a+/–, and Tnfrsf1a–/– fibroblasts (n = 4) 24 hours after 
TNF stimulation. (B) Measurement of Tnfrsf1a+/+, Tnfrsf1a+/–, and Tnfrsf1a–/– fibroblast survival after stimulation with different concentrations of TNF/CHX 
(10 μg/ml). Both Tnfrsf1a+/+ and Tnfrsf1a+/– cells undergo apoptosis to a similar extent. (C) Caspase-8 Western blot after TNF/CHX stimulation (1,000 
IU/ml and 10 μg/ml) at different time points. The intensity of cleaved caspase-8 (p43/p41) bands was normalized to actin levels. (D) Body temperature 
of Tnfrsf1a+/+ (n = 4), Tnfrsf1a+/– (n = 5), and Tnfrsf1a–/– (n = 3) mice after i.p. injection with 1 μg TNF plus 20 mg GalN. Tnfrsf1a+/+ and Tnfrsf1a+/– mice 
were euthanized for sampling when their body temperature dropped to 30°C. (E and F) Hepatocyte cell death parameters after i.p. injection with TNF 
(1 μg/mouse) plus GalN (20 mg/mouse). After challenge, mice were sacrificed when their body temperature dropped to 30°C. (E) Serum ALT and 
AST and (F) DEVDase activity in liver. (G and H) Cell death and caspase activation in CD45–CD31+PI– tumor neovascular endothelial cells. B16BL6 
melanoma-bearing mice were injected s.c. paralesional with 15 μg TNF plus 5,000 IU IFN-γ or with PBS, and 24 hours later tumors were excised and 
(G) cell death and (H) caspase activation were measured by FACS using annexin V and Flica staining, respectively. Actual percentages of cell death 
in the PBS-treated animals were 63%, 26%, and 50% (G) and 55%, 55%, and 73% (H) for Tnfrsf1a+/+, Tnfrsf1a+/–, and Tnfrsf1a–/–, respectively. Data 
represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test).
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Hence, systemic use with high doses of TNF seemed impossible (2, 
4, 42) unless a more substantial increase in MTD (up to 10 fold, as 
proposed; ref. 5) could be obtained.
We demonstrate here that deletion of one functional Tnfrsf1a allele 
leads to complete protection against challenge with a dose of TNF 
that is at least 40 times of LD100. This protective haploinsufficiency 
is likely mediated by dampening the proinflammatory effect of 
TNF. Hemizygous mice challenged with TNF exhibited significantly 
reduced inflammation, as shown by a 32-fold reduction in serum 
IL-6 levels, compared with Tnfrsf1a+/+ mice. This decreased inflam-
mation seems to be due to reduced expression of NF-κB–dependent 
genes, which was also reflected in downmodulation of a number of 
cytokines in serum as well as reduction of NO metabolites. These 
results suggest that the TNF resistance of Tnfrsf1a+/– animals can be 
explained by a combined reduction of multiple toxic mediators, a 
hypothesis that we confirmed by inhibiting 3 such toxic mediators 
(namely IL-1, ROS, and type I IFNs), which led to cumulative protec-
tion against TNF. Interestingly, reduction of p55TNFR levels by 50% 
does not affect physiological functions of TNF, such as antibacterial 
resistance and secondary lymphoid organ structure and function.
Figure 6
Increased MTD and anticancer 
effects in Tnfrsf1a+/– mice. Antitu-
mor effect and survival after 10 days 
of high-dose TNF (50 μg/mouse) 
plus IFN-γ treatment (5,000 IU). 
(A) Toxicity of TNF plus IFN-γ in 
Tnfrsf1a+/+ mice (black triangles) 
and Tnfrsf1a+/– mice (blue circles). 
Healthy tumor-free mice (continu-
ous line) and B16BL6 melanoma-
bearing mice (dotted line) were 
injected daily with different doses of 
TNF plus IFN-γ for 10 days. Healthy 
mice were injected i.p., whereas 
tumor-bearing mice were injected 
s.c. paralesional. The horizontal line 
represents LD50. (B) B16BL6 mela-
noma-bearing Tnfrsf1a+/+, Tnfrsf1a+/–, 
and Tnfrsf1a–/– mice were treated 
daily by paralesional s.c. injection 
with PBS (white symbols; Tnfrsf1a+/+, 
n = 5; Tnfrsf1a+/–, n = 3; Tnfrsf1a–/–, 
n = 4) or high-dose TNF (black sym-
bols; Tnfrsf1a+/+, n = 6; Tnfrsf1a+/–, 
n = 10; Tnfrsf1a–/–, n = 6) plus IFN-γ. 
Tnfrsf1a–/– mice had to be euthanized 
due to large tumor size (indicated 
by //). (C) LLC-bearing mice were 
treated daily with PBS (white sym-
bols; Tnfrsf1a+/+, n = 6; Tnfrsf1a+/–, 
n = 9; Tnfrsf1a–/–, n = 4) or TNF/IFN-γ 
(black symbols; Tnfrsf1a+/+, n = 5; 
Tnfr sf1a+/–, n = 13; Tnfrsf1a–/–, n = 9). 
(D) B16BL6 melanoma-bearing Tnfr-
sf1afl/fl and Villin-Cre Tnfrsf1afl/fl mice 
were treated daily by paralesional 
injection of 12 μg TNF plus IFN-γ 
(5,000 IU) for 10 days (Tnfrsf1afl/fl, 
n = 20 and Villin-Cre Tnfrsf1afl/fl, 
n = 16). Tnfrsf1afl/fl PBS-treated mice 
(n = 11) had to be euthanized 
because of their large tumor size 
(indicated by //). Data represent mean 
± SEM. *P < 0.05, ***P < 0.001, Stu-
dent’s t test in B and C (left) and log-
rank test (right); in tumor size index 
(TSI) graphs, compared with PBS- 
and TNF/IFN-γ–treated Tnfrsf1a+/– 
(A–C) or TNF/IFN-γ–treated Tnfr-
sf1afl/fl and Villin-Cre Tnfrsf1afl/fl (D).
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Figure 7
Antibodies against p55TNFR protect against TNF toxicity, increase MTD, and allow safe anticancer therapy. (A) TNF (30 μg) was administered 
to mice pretreated i.p. with different doses of anti-mp55TNFR monoclonal antibodies (10 mg/ml, n = 5; 5 mg/ml, n = 5; 2.5 mg/ml, n = 4) or PBS 
(n = 7) or control hamster IgG1 (10 mg/ml, n = 5). (B) Antitumor effects and (C) survival in antitumor experiments on Tnfrsf1a+/+ mice treated for 
10 days paralesionally with TNF (25 μg) plus IFN-γ (5,000 IU) (black symbols) or PBS (white symbols) and cotreated i.p. daily with PBS (black), 
control (red), or anti-mp55TNFR antibodies (gray). (D) Toxicity study of TNF/IFN-γ in B16BL6 melanoma-bearing Tnfrsf1a+/+ mice cotreated i.p. 
with PBS, control antibodies, or anti-mp55TNFR antibody for 10 days. (E) Human TNFRSF1A knockin mice treated i.p. with anti-hp55TNFR 
monoclonal antibodies (10 mg/ml, n = 6 or 4 mg/ml, n = 6) or control antibody (10 mg/ml, n = 6) and injected with 50 μg TNF or PBS (n = 6). (F) 
Antitumor effects and (G) survival in antitumor experiments in human TNFRSF1A knockin mice treated with PBS (white symbols) or TNF/IFN-γ 
(black symbols) and daily i.p. coadministration of PBS (n = 6), control (n = 6), or anti-hp55TNFR antibodies (n = 12). (H) Toxicity study of TNF/
IFN-γ in B16BL6 melanoma-bearing human TNFRSF1A knockin mice i.p. cotreated with PBS, control antibody, or anti hp55TNFR antibody. The 
horizontal line in D and H represents LD50. In the TSI graphs, “***” is between PBS and TNF/IFN-γ–treated p55TNFR antibody groups. All data 
represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test in B and F and log-rank test in A, C, E, and G).
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mice humanized for the TNFRSF1A gene (combined with anti-hp55-
TNFR antibodies). Systemic inhibition of p55TNFR was clearly very 
protective against TNF toxicity, while the antitumor activity remained 
functional and led to an increase of 4 to 5 times of LD50.
The dosing of p55TNFR-inhibiting antibodies in these experi-
ments is crucial and should lead to a Tnfrsf1a+/–-like phenotype. 
Treatment with an insufficient amount of antibody might lead to 
lethal toxicity, while excessive antibody may block TNF-induced 
antitumor responses. In order to translate our findings to the 
clinic, it may be necessary to generate a reliable prediction method 
to quantify the available or signaling-competent p55TNFR. Future 
studies should investigate the stability and range of p55TNFR 
expression in human samples and correlate antibody dosing with 
TNF-induced responses.
To provide further mechanistic explanation for our findings, we 
suggest a model in which p55TNFR-induced inflammation is a 
dynamic system, which, in response to a given TNF stimulus, leads 
to an adequate activation of NF-κB and MAPK signaling. The magni-
tude of an inflammatory response not only depends on TNF dosage 
but also on the amount of available p55TNFR, a mechanism which 
is also applied in pathophysiology by shedding of the p55TNFR (46). 
Halving the amount of p55TNFR leads to a halving of the concen-
tration of multiple (n) toxic inflammatory mediators, such as IL-1, 
IFN-β, IL-17 and others, identified previously (24–28), leading to a 
robust (2n) combined protection against TNF in Tnfrsf1a+/– mice. In 
contrast, TNF-induced cell death of TNF-sensitive cells (IECs, tumor 
blood vessels) behaves like a binary system, which can still induce the 
necessary threshold when p55TNFR levels are halved.
In conclusion, we have found a way to increase the safety of the 
potent anticancer effect of TNF, and we provide evidence that this 
approach may be directly translatable to the clinic. Our results 
uncover the cellular basis of systemic TNF toxicity and reveal an 
IEC-specific haploinsufficiency of p55TNFR, which allows miti-
gation of TNF toxicity without loss of antitumor efficacy. Our 
results also highlight the differential quantitative requirements 
for the p55TNFR in diverse physiological phenomena and provide 
a framework for the development of more selective therapeutic 
interventions using the TNF/TNFR system.
Methods
Animals. Tnfrsf1a knockout mice generated by M. Rothe (12) were a gift 
of H. Bleuthmann (Hoffmann-La Roche, Basel, Switzerland). Other mice 
deficient in the Tnfrsf1a gene, generated by gene targeting (13, 14), were 
purchased from The Jackson Laboratories. Most of the experiments were 
performed on the Tnfrsf1a–/– mice generated by M. Rothe. There was no 
specific reason for this choice. Crosses with C57BL/6J mice were performed 
to obtain Tnfrsf1a+/– F1 mice. Ifnar1 knockout mice were provided by D. 
Bonaparte (Gulbenkian Institute of Science, Oeiras, Portugal). nu/nu mice 
were purchased from Janvier. Mice were maintained in conventional tem-
perature-controlled, air-conditioned animal houses with a 14- to 10-hour-
light/dark cycle and received food and water ad libitum. Experiments with 
nu/nu and all other mice were performed in the SPF VIB animal house, 
and experiments with the Tnfrsf1afl and human TNFRSF1A knockin mice 
(described in Supplemental Figures 4 and 8, respectively) were performed 
in the Alexander Fleming Centre animal house. Experiments were per-
formed when the mice were 8–12 weeks old. Conditional Tnfrsf1a reacti-
vation mutant mice (Tnfrsf1aflNeo mice) were previously described (35). In 
short, the Tnfrsf1aflNeo mouse strain was generated by insertion of a floxed 
neo into intron 5 of the locus to create this conditional gain-of-function 
allele. The presence of the neo prevents expression of the gene.
The anticancer effect of TNF has been shown to be essential-
ly directed to the neovascular endothelium of tumors, causing 
endothelial cell death and vascular dysfunction (11, 19, 20). In 
order to understand and interfere with the mechanism of sys-
temic toxicity of TNF, it is critical to identify cell types that are 
essential in this process. TNF-induced toxicity previously has 
been shown to be associated with hypotension (43), liver damage 
(44), and severe bowel damage (31). In this study, we have made 
use of 2 informative genetic approaches (i.e., Tnfrsf1a conditional 
knockout and reactivation mice), which basically provided us with 
the novel finding that expression of p55TNFR on IECs (and not 
on endothelial, hepatocyte, or myeloid cells) is essential to cause 
TNF-induced lethality: mice expressing Tnfrsf1a+/+ levels in IECs 
in a Tnfrsf1a+/– background regain TNF sensitivity, while IEC-spe-
cific Tnfrsf1a–/– mice become TNF resistant. We found that TNF-
induced inflammatory gene expression in intestinal epithelium 
is strongly reduced in IEC-specific Tnfrsf1a–/– mice as well as in 
Tnfrsf1a+/– mice and observed a clear association between lethality 
and loss of intestinal epithelial permeability, which might lead to 
influx of gut bacteria or bacterial antigens in the system, as previ-
ously suggested (31, 32, 45).
p55TNFR-dependent apoptosis was addressed both in vitro by 
TNF/CHX and in vivo by using the TNF/GalN and TNF/ActD 
models, in which massive liver apoptosis is induced (38). Fibro-
blasts derived from Tnfrsf1a+/– mice were equally sensitive to TNF/
CHX–induced apoptosis as cells from Tnfrsf1a+/+ mice and showed 
no reduced caspase-8 cleavage. In the same Tnfrsf1a+/– fibroblasts, 
inflammatory gene induction was strongly reduced compared 
with that in Tnfrsf1a+/+ cells, as was found in macrophages. Clear-
ly, the receptor-stimulated activation of transcription factors (as 
NF-κB) and kinases (MAPK), leading to inflammation, was sensi-
tive to p55TNFR levels, while the activation of caspase-8, leading 
to apoptosis, was not. Also, in the in vivo models, Tnfrsf1a+/+ and 
Tnfrsf1a+/– cells appeared equally responsive and showed compar-
able levels of caspase activation, although the response in the 
TNF/GalN and TNF/ActD models appeared slightly delayed in 
Tnfrsf1a+/– mice. Also, a similar degree of apoptosis was measured 
in the typically TNF-sensitive IECs of Tnfrsf1a+/+ and Tnfrsf1a+/– 
mice and in the tumor-associated neovascular endothelial cells 
after treatment with TNF/IFN-γ, since Tnfrsf1a+/+ and Tnfrsf1a+/– 
mice showed comparable induction of apoptosis, which is essen-
tial for induction of tumor regression (7, 20).
Full antitumor activity was obtained in tumor-bearing mice by 
daily injections of TNF in combination with IFN-γ for 10 days (1). We 
investigated the efficacy and potential toxicity of TNF/IFN-γ for 10 
days as a treatment for cancer in mice bearing s.c. B16BL6 melanoma. 
LD50 of a 10-day treatment was increased in Tnfrsf1a+/– mice by more 
than 8 fold. This therapeutic window is close to the required 10-fold 
factor proposed by Lejeune and colleagues (6), who concluded that 
protecting mice or human patients against a 10-fold toxic dose with 
retention of anticancer effects should be sufficient to allow systemic 
therapy with TNF (5). Our results indicate that TNF/IFN-γ treatment 
is effective against tumors in Tnfrsf1a+/– mice. We tested this hypoth-
esis in cancer models (B16BL6 and LLC) and found that TNF/IFN-γ 
therapy indeed led to highly significant tumor regression as well as 
survival. We conclude that reduction of p55TNFR levels by 50% great-
ly reduces TNF-induced toxicity without diminishing the antitumor 
effects. To provide proof of principle for pharmacologic treatment 
based on our approach, we inhibited p55TNFR both in normal mice 
(with anti-mp55TNFR antibodies) and in newly generated mutant 
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they reached a tumor size index of about 80 mm², at which time the mice 
received a single injection of 15 μg TNF plus 5,000 IU IFN-γ. The tumors 
were isolated 24 hours later and processed mechanically (by cutting and 
passing through a 19 G needle) and enzymatically (30 minutes 37°C in 
a collagenase solution) to obtain single cell suspensions. Red blood cells 
were lysed in an ACK lysis buffer for 5 minutes. Staining was done on 
5 × 105 cells of each sample. For annexin V staining, cells were incubated 
for 30 minutes at room temperature with anti-CD31, anti-CD45, and 
anti-annexin V. 7-AAD staining was always negative (data not shown). 
For the Flica staining (AbD Serotec), cells were incubated for 1 hour at 
37°C in 200 μl DMEM, 25% FCS, and 1 μl of the 150× Flica stock. The 
cells were then washed and stained with anti-CD31 and anti-CD45 for 
30 minutes. Endothelial cells in these cell suspensions were identified as 
CD45 negative, and CD31-positive cells and SYTOX Red-positive cells 
were excluded. This population was analyzed for annexin V and Flica 
staining by FACS.
Determination of IL­6 and other cytokines in serum. IL-6 was measured by 
using an IL-6–dependent 7TD1 hybridoma cell line (48). Levels of IL-1α, 
IL-1β, MCP-1, MIP1b, and Rantes were measured with the Bio-plex system 
(Bio-Rad) according to the manufacturer’s instructions.
Gene induction experiments. Liver and intestine samples were collected in 
RNA Later (Qiagen). RNA was isolated with the RNeasy Mini Kit (Qia-
gen) according to the manufacturer’s instructions. RNA concentration 
was measured with the Nanodrop1000 (Thermo Scientific), and 1 μg 
RNA was used to prepare cDNA with SuperScript II (Invitrogen). qPCR 
was performed using the SYBR Green 1 Master Mix (Roche) and the 
LightCycler 480 (Roche). The best-performing housekeeping genes for 
each tissue were determined with Genorm (49). Values are presented as 
relative expression normalized to the geometric mean of the 2 selected 
housekeeping genes.
Detection of membrane p55TNFR by flow cytometry. BMDMs were col-
lected, washed, and incubated with antibodies in phosphate-buffered 
saline supplemented with 0.2% sodium azide-BDH and 10% FBS. The 
antibodies were 0.5 μg primary hamster anti-mp55TNFR antibody 
(clone 55R-286, BD Pharmingen) and 0.75 μg biotinylated goat anti-
hamster IgG (Vector Laboratories), followed by 0.5 μg streptavidin 
SAv-PE (BD Pharmingen), each of which was incubated for 30 min-
utes at 4°C. p55TNFR expression was measured by flow cytometry on 
a Coulter EPICS XL-MCL Flow Cytometer (Coulter Co.) and analyzed 
with the WinMDI 2.8 software.
TNF­binding assay. BMDMs (2 × 106 cells per tube) were incubated for 
at least 3 hours at 4°C with radiolabeled 125I-hTNF (Amersham), which 
binds only to p55TNFR. As a control for nonspecific binding, the same 
experiment was performed in the presence of a 500-fold excess of unla-
beled hTNF. After incubation, the cells were washed 4 times with PBS at 
4°C to remove the unbound ligand, and radioactivity of the cell pellet was 
measured with a gamma counter (Beckman). Nonspecific binding was sub-
tracted from the total activity.
p55TNFR ELISA. Whole organ samples were homogenized in ice-
cold buffer (PBS, 0.5% CHAPS, protease inhibitors [Complete, Roche]). 
Homogenates were centrifuged for 30 minutes at 20,000 g and 4°C, after 
which the supernatant was collected and stored at –80°C.
Protein concentration was determined by the Bradford method (Bio-
Rad). p55TNFR levels were determined with the Quantikine sp55 TNFR 
ELISA Kit (R&D Systems). The levels shown are normalized to the 
Tnfrsf1a+/+ levels, which were set as 100%.
Statistics. Survival curves (Kaplan-Meier plots) were compared using a 
log-rank test. Results (mean ± SEM) were compared with a 2-tailed Stu-
dent’s t test. Final mortality data were compared using a Fisher’s exact test. 
P values of less than 0.05 were considered significant.
Generation of Tnfrsf1a conditional knockout mice. The Tnfrsf1afl/fl mouse 
strain was generated using standard gene-targeting techniques. In brief, 
a targeting vector has been generated to induce homologous recombi-
nation in ES cells, with exons 2–5 flanked by loxP sites, which upon 
recombination will result in a frame shift mutation. Upstream of the 
first loxP site, a flipped neo cassette was inserted to allow for antibi-
otic resistance selection, and flanking sequences of 3.6 and 2.8 kb 5′ 
and 3′ completed the vector, fulfilling the homologous recombination 
requirements. All sequences of the mouse Tnfrsf1a gene were derived by 
PCR amplification from the respective BAC clone. All exons have been 
sequenced, and integrity of the sequence was confirmed (Supplemental 
Figure 4A). The vector was introduced in 129/ola ES cells, and clones 
having successfully recombined were used for the generation of chimae-
ras (Supplemental Figure 4B). Chimeric mice were crossed to C57BL/6J 
mice, and offspring having germline transmission of the mutated allele 
were used for expansion. The mice were crossed to FLP deleter mice for 
the neo cassette to be removed. Then, Tnfrsf1afl/fl mice were crossed with 
Cre deleter mice for the generation of Tnfrsf1 complete knockout mice, 
designated as Tnfrsf1aΔ/Δ mice. The neo cassette removal was success-
fully. The Tnfrsf1afl/fl mouse line was expanded, and the mice were back-
crossed to C57BL/6J for at least 6 generations. After crossing the Tnfr­
sf1afl/fl mice with deleter cre mice, the deficiency in p55TNFR expression 
in Tnfrsf1aΔ/Δ mice was confirmed in BMDMs by FACS analysis (Supple-
mental Figure 4C) as previously described (47).
Generation of human TNFRSF1A knockin mice. Human TNFRSF1A 
knockin mice were generated by gene targeting in C57BL/6 ES cells. 
A targeting vector containing human and mouse Tnfrsf1a genomic 
sequences was engineered for the expression of a recombinant tran-
script consisting of the mouse 5′ UTR, signal peptide, and 3′ UTR 
sequences flanking the human Tnfrsf1a-coding sequences and express-
ing the mature hp55TNFR protein. The transgene was knocked-in into 
the mouse locus, thereby inactivating the mouse gene and expressing 
the human gene under the mouse regulatory sequences. hp55TNFR in 
these mice was present and functional in all tissues and assays tested, 
giving to these “humanized” mice a normal TNFRSF1A+/+ phenotype 
(Supplemental Figure 8 and data not shown).
Cytokines, tempol, IL­1RA, anti­mp55TNFR and anti­hp55TNFR antibodies. 
Recombinant mouse TNF and IFN-γ were expressed in Escherichia coli and puri-
fied in our laboratories. TNF had a specific activity of 1.0 × 109 IU/mg. IFN-γ 
had a specific activity of 1.1 × 109 IU/mg. Endotoxin in the cytokine prepa-
rations was below the detection limit of a Limulus amoebocyte lysate assay. 
Cytokines and LPS were diluted in endotoxin-free PBS (GIBCO, Invitrogen) 
immediately before injection. Tempol, 6 mg per mouse (Sigma-Aldrich) was 
injected 45 minutes before TNF injection (28). IL-1RA (Anakinra), 650 μg 
per mouse, was injected together with TNF and again 4 and 8 hours after 
TNF. The neutralizing hamster anti-mp55TNFR IgG1 antibody (55R170) 
was bought from R&D Systems. It was pure and contained no detectable LPS 
contamination. A control hamster IgG1 antibody was bought from Innova-
tive Research. The anti-mp55TNFR was specific for the p55TNFR, because 
it protected Tnfrsf1a+/+ mice against LPS but not Tnfrsf1a–/– mice against LPS 
(data not shown). The ultrapure neutralizing anti-hp55TNFR antibody 
m5R16 was generated and provided by UCB. This antibody is a PEGylated 
F(ab)′ fragment and is highly specific for the hp55TNFR, as indicated by 
its ability to block TNF-induced biological activities (e.g., TNF lethality) in 
human TNFRSF1A knockin mice but not in Tnfrsf1a+/+ mice (see Figure 7E 
and data not shown). As a control, a purified PEGylated control F(ab)′ frag-
ment (mA33) was provided by UCB.
Measuring tumor neovascular endothelial cell caspase activation and cell 
death. Eight-week-old mice were injected with 6 × 105 B16BL6 cells in the 
shaved right thigh. Tumors were allowed to grow for 12 to 14 days until 
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